» Articles » PMID: 8320173

Antimetastatic Activity of Polymeric RGDT Peptides Conjugated with Poly(ethylene Glycol)

Overview
Specialty Oncology
Date 1993 May 1
PMID 8320173
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Polymeric peptides containing defined repetitive or cyclic structures of RGDT sequence, (RGDT)n (n = 1 to 11) and cyclo(RGDT)n (n = 2 to 4), at a dose of 500 micrograms exhibited an inhibitory effect on experimental lung metastasis upon co-injection with tumor cells and the magnitude of the effect increased in parallel with the increase of degree of repetition of the RGDT sequence. The conjugation of (RGDT)n (n = 1, 5, 11) with poly(ethylene glycol), PEG as a polymeric carrier led to enhanced inhibition of lung metastasis in proportion to the degree of RGDT sequence repetition and in a dose-dependent manner. Multiple i.v. administrations of PEG-(RGDT)11, at 2-day and 3-day intervals before the excision of primary tumors, effectively inhibited spontaneous lung metastasis by s.c. inoculation of tumors, whereas (RGDT)11 exhibited inhibition of lung metastasis only when given at 2-day intervals. This indicates that the conjugation of PEG with (RGDT)n allowed the prolongation of administration interval, implying a sustained inhibitory effect on tumor metastasis. In support of this supposition, a decrease in the arrest of radiolabeled tumor cells in the lungs was observed when PEG-(RGDT)11 was co-injected i.v. with tumor cells, or injected i.v. one day before tumor inoculation. In contrast, (RGDT)11 significantly inhibited the tumor cell arrest in the lungs only upon co-injection with tumor cells. We also noted that (RGDT)n, cyclo(RGDT)n and PEG-(RGDT)11 inhibited tumor cell invasion into Matrigel in a concentration-dependent manner and in proportion to the degree of RGDT sequence repetition, indicating that the peptide-mediated antimetastatic effect is partly associated with the anti-invasive potential. Thus, the conjugation of anti-cell adhesive and anti-metastatic RGDT peptide with PEG might provide a therapeutically promising basis for the prevention of cancer metastasis ("anti adhesion therapy").

Citing Articles

Anti-metastatic therapy by urinary trypsin inhibitor in combination with an anti-cancer agent.

Kobayashi H, Shinohara H, Gotoh J, Fujie M, Fujishiro S, Terao T Br J Cancer. 1995; 72(5):1131-7.

PMID: 7577458 PMC: 2033948. DOI: 10.1038/bjc.1995.476.

References
1.
Humphries M, Yamada K, Olden K . Investigation of the biological effects of anti-cell adhesive synthetic peptides that inhibit experimental metastasis of B16-F10 murine melanoma cells. J Clin Invest. 1988; 81(3):782-90. PMC: 442526. DOI: 10.1172/JCI113384. View

2.
Terranova V, Hujanen E, Martin G . Basement membrane and the invasive activity of metastatic tumor cells. J Natl Cancer Inst. 1986; 77(2):311-6. View

3.
Liotta L, Rao C, Barsky S . Tumor invasion and the extracellular matrix. Lab Invest. 1983; 49(6):636-49. View

4.
Suzuki S, Oldberg A, Hayman E, Pierschbacher M, Ruoslahti E . Complete amino acid sequence of human vitronectin deduced from cDNA. Similarity of cell attachment sites in vitronectin and fibronectin. EMBO J. 1985; 4(10):2519-24. PMC: 554538. DOI: 10.1002/j.1460-2075.1985.tb03965.x. View

5.
Ruoslahti E, Pierschbacher M . Arg-Gly-Asp: a versatile cell recognition signal. Cell. 1986; 44(4):517-8. DOI: 10.1016/0092-8674(86)90259-x. View